×
Biofrontera Inventory 2021-2025 | BFRI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biofrontera inventory from 2021 to 2025. Inventory can be defined as the total value of inventories in all stages of completion.
View More
Biofrontera Inventory 2021-2025 | BFRI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biofrontera inventory from 2021 to 2025. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$213.3B
Amgen (AMGN)
$158.5B
Gilead Sciences (GILD)
$134.6B
Vertex Pharmaceuticals (VRTX)
$118.1B
Bristol Myers Squibb (BMY)
$96.4B
CSL (CSLLY)
$81.2B
GSK (GSK)
$74.3B
Regeneron Pharmaceuticals (REGN)
$58.6B
Alnylam Pharmaceuticals (ALNY)
$41.8B
Argenex SE (ARGX)
$34.6B
BioNTech SE (BNTX)
$26.4B
Royalty Pharma (RPRX)
$20B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.3B
Illumina (ILMN)
$15.2B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.1B
Exelixis (EXEL)
$12.1B
Moderna (MRNA)
$12.1B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.4B
Exact Sciences (EXAS)
$9.5B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.2B
Roivant Sciences (ROIV)
$7.8B
Legend Biotech (LEGN)
$7.6B